[2 years' experiences with cavernosal autoinjection therapy].
Between February 1985 and January 1987, 186 patients with erectile dysfunction were selected for cavernosal autoinjection therapy (CAT). After more than 4800 protocolled autoinjections and 10-230 CAT/pt., no cavernous fibrosis, penile deviation or cavernitis occurred. The only serious side effects were prolonged erections in about 10% during diagnostic and less than 1% during therapeutic use. These prolonged erections could be easily treated by puncture and aspiration of corpora cavernosa or intracavernosal injection of Metaraminol.
D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D008297:Male; D008680:Metaraminol / Q000008:administration & dosage; D010208:Papaverine / Q000008:administration & dosage*; D010410:Penile Erection / Q000187:drug effects; D010413:Penis / Q000187:drug effects; D010646:Phentolamine / Q000008:administration & dosage / Q000031:analogs & derivatives*
D008680:Metaraminol; D010208:Papaverine; D010646:Phentolamine
2 Jahre Erfahrungen mit der Schwellkörper-Autoinjektions-Therapie (SKAT).